• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ATX

AMPLIA THERAPEUTICS LIMITED - Charts / Financials

5.00% ! 5.7¢
Market Cap $22.11M  !
Healthcare Biotechnology
Add to My Watchlist

Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development... Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The Company's pipeline includes narmafotinib (AMP945) and AMP886. narmafotinib is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company's second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Day
Open 6.1¢   Day High 6.1¢   Day Low 5.6¢
Daily Volume 490902
Bids   Sellers
Number Price Volume   Number Price Volume
2 5.7¢ 42618   2 6.0¢ 93000

Directors & Senior Management

Dr. Christopher John Burns Chief Executive Officer, Managing Director, Director
Mr. Hamish George Chief Financial Officer
Dr. Mark Devlin Chief Scientific Officer
Dr. Jason Lickliter Chief Medical Officer
Mr. Andrew John Cooke Company Secretary
Mr. Warwick Bonner Tong Non-Executive Independent Chairman of the Board
Mrs. Jane Bell Non-Executive Independent Director
Dr. Robert Peach Non-Executive Independent Director

Data source: Refinitiv

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
5.7¢ 		Change
-0.003(5.00%) 		Mkt cap ! $22.11M
Open High Low Value Volume
6.1¢ 6.1¢ 5.6¢ $27.87K 490.9K

Buyers (Bids)

No. Vol. Price($)
2 42618 5.7¢
 

Sellers (Offers)

Price($) Vol. No.
6.0¢ 93000 2
View Market Depth
Last trade - 15.58pm 13/06/2025 (20 minute delay) ?

Top Stories

Week 24 Wrap: WW3 looms (again); US econ data tepid & silver surfing

By and large, I don't think I'd be without peers when I said the biggest thing that happened this week was on energy markets.
Clinuvel shares dip, even as CEO comes back from temp leave After Clinuvel's (ASX:CUV) CEO Dr. Philippe Wolgen took time off back in March to respond to an "acute medical condition," it wasn't...
HotCopper Highlights, Week 24: Israel boosts Energy; Meeka eyes production & Mag7 back Good Afternoon and welcome to HotCopper Highlights for Week 24 of the year, I’m Jon Davidson. In this segment we look at some of the...
Zip's stunning comeback: Is this the start of a $14 revival? Just when the market had written it off… Zip Co (ASX: ZIP) has come roaring back to life. The Buy Now, Pay Later company stunned investors last Wednesday with a 15% surge in its share price soon after upgrading its full-year earnings forecast to at least $160 million @ up from $153 million...
Iberian expansion: Megado turns to Europe with Spanish copper mines Megado Minerals has added the Iberian Copper Project in Spain to its expanding collection after buying an 80% interest in Iberian Copper.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.